Please assess the completion status of the following clinical trial:

Trial Title: GV1001 and Gemcitabine in Sequential Combination to Gemcitabine Monotherapy in Pancreatic Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Histologically or cytologically confirmed, unresectable, locally advanced, or metastatic adenocarcinoma of the pancreas.~2. Adequate hematological parameters:~   Hemoglobin \>/= 9.5 g/dL \[SI units, 5.9 mmol/L\] WBC \>/= 3000/mm3 \[SI units, \>/= 3 x 109/L\] Platelets \>/= 100,000/mm3 \[SI units, \>/= 100 x 109/L\]~3. Adequate baseline liver function:~   Total Bilirubin \< 3x ULN and~   Without liver metastases:~   AST (SGOT) \</= 2.5 x ULN ALT (SGPT) \</= 2.5 x ULN~   With liver metastases:~   AST (SGOT) \</= 5 x ULN ALT (SGPT) \</= 5 x ULN~4. Serum creatinine \</= 1.5 mg/dL \[SI units, 132 µmol/L\].~5. Performance status ECOG 0-1.~6. Male or female 18 - 75 years inclusive.~7. Minimum life expectancy of 3 months.~8. Written informed consent.~Exclusion Criteria:~1. Treatment with chemotherapy for pancreatic cancer.~2. Treatment with other investigational drugs within the last 4 weeks prior to inclusion~3. Immune-suppressive therapy \<4 weeks prior to inclusion~4. Chronic corticosteroid use except for asthma inhalers / topical use~5. Radiotherapy within 8 weeks of randomisation.~6. Other prior malignancies except for adequately treated non-melanoma skin cancers (BCC, SCC) and carcinoma in situ of the cervix.~7. Known diagnosis of HIV (AIDS), Hepatitis B, C.~8. Known history of or co-existing autoimmune disease.~9. Known CNS metastases.~10. Clinically significant serious disease or organ system disease not currently controlled on present therapy.~11. Pregnancy or lactation.~12. Women of childbearing potential not using reliable and adequate contraceptive methods\*~13. Known sensitivity to any components of vaccine, gemcitabine or GM-CSF.~14. Unable for any other reason to comply with the protocol (treatment or assessments).~    * Adequate contraceptive methods are defined as the use of oral, implanted, injectable, mechanical or barrier products for the prevention of pregnancy; or women who are practising abstinence; or where the partner is sterile, for example a vasectomy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Gemcitabine (Type: ACTIVE_COMPARATOR): Gemcitabine alone treatment.
- GV1001 (Type: EXPERIMENTAL): GV1001 in sequential combination with Gemcitabine

Based on this trial design, predict the completion outcome and termination type (if applicable).